NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

AI Briefing

• – NRx Pharmaceuticals welcomes President Trump's Executive Order to accelerate the approval of psychedelic medications for depression, PTSD, and suicidality.
• – The Order aims to increase access to life-saving treatments for serious mental illness in America.
• – NRx Pharmaceuticals is committed to developing innovative psychedelic-based treatments for mental health conditions.